403 related articles for article (PubMed ID: 30042077)
61. Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development.
Pillinger T; Howes OD; Correll CU; Leucht S; Huhn M; Schneider-Thoma J; Gaughran F; Jauhar S; McGuire PK; Taylor DM; Young AH; McCutcheon RA
Lancet Psychiatry; 2023 Nov; 10(11):860-876. PubMed ID: 37774723
[TBL] [Abstract][Full Text] [Related]
62. Mortality risk from long-term treatment with antipsychotic polypharmacy vs monotherapy among adults with serious mental illness: A systematic review and meta-analysis of observational studies.
Buhagiar K; Templeton G; Blyth H; Dey M; Giacco D
Schizophr Res; 2020 Sep; 223():18-28. PubMed ID: 32948381
[TBL] [Abstract][Full Text] [Related]
63. Benefits and harms of antipsychotic drugs in drug-naïve patients with psychosis: A systematic review.
Danborg PB; Gøtzsche PC
Int J Risk Saf Med; 2019; 30(4):193-201. PubMed ID: 31561392
[TBL] [Abstract][Full Text] [Related]
64. Placebo response in antipsychotic clinical trials: a meta-analysis.
Rutherford BR; Pott E; Tandler JM; Wall MM; Roose SP; Lieberman JA
JAMA Psychiatry; 2014 Dec; 71(12):1409-21. PubMed ID: 25321611
[TBL] [Abstract][Full Text] [Related]
65. Choice of observational study design impacts on measurement of antipsychotic risks in the elderly: a systematic review.
Pratt N; Roughead EE; Salter A; Ryan P
BMC Med Res Methodol; 2012 Jun; 12():72. PubMed ID: 22682666
[TBL] [Abstract][Full Text] [Related]
66. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials.
Nitta M; Kishimoto T; Müller N; Weiser M; Davidson M; Kane JM; Correll CU
Schizophr Bull; 2013 Nov; 39(6):1230-41. PubMed ID: 23720576
[TBL] [Abstract][Full Text] [Related]
67. Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia: A Meta-analysis Study.
Tseng PT; Chen YW; Chung W; Tu KY; Wang HY; Wu CK; Lin PY
Medicine (Baltimore); 2016 Jan; 95(4):e2475. PubMed ID: 26825886
[TBL] [Abstract][Full Text] [Related]
68. Antipsychotic combinations in schizophrenia.
Gastaldon C; Papola D; Ostuzzi G
Epidemiol Psychiatr Sci; 2017 Oct; 26(5):462-465. PubMed ID: 28578741
[TBL] [Abstract][Full Text] [Related]
69. Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials.
Burschinski A; Schneider-Thoma J; Chiocchia V; Schestag K; Wang D; Siafis S; Bighelli I; Wu H; Hansen WP; Priller J; Davis JM; Salanti G; Leucht S
World Psychiatry; 2023 Feb; 22(1):116-128. PubMed ID: 36640396
[TBL] [Abstract][Full Text] [Related]
70. Antipsychotic Polypharmacy Among Patients With Schizophrenia in Africa: A Systematic Review and Meta-Analysis.
Ayenew W; Asmamaw G; Bitew T
Int J Neuropsychopharmacol; 2021 Dec; 24(12):956-964. PubMed ID: 34245271
[TBL] [Abstract][Full Text] [Related]
71. Long-term effects of antipsychotics on mortality in patients with schizophrenia: a systematic review and meta-analysis.
Jia N; Li Z; Li X; Jin M; Liu Y; Cui X; Hu G; Liu Y; He Y; Yu Q
Braz J Psychiatry; 2022 Nov; 44(6):664-673. PubMed ID: 36709510
[TBL] [Abstract][Full Text] [Related]
72. Mortality Risk of Atypical Antipsychotics for Behavioral and Psychological Symptoms of Dementia: A Meta-Analysis, Meta-Regression, and Trial Sequential Analysis of Randomized Controlled Trials.
Yeh TC; Tzeng NS; Li JC; Huang YC; Hsieh HT; Chu CS; Liang CS
J Clin Psychopharmacol; 2019; 39(5):472-478. PubMed ID: 31433335
[TBL] [Abstract][Full Text] [Related]
73. Review and meta-analysis of add-on tranylcypromine with antipsychotic drugs for the treatment of schizophrenia with predominant negative symptoms: a restoration of evidence.
Ulrich S; Messer T
Curr Med Res Opin; 2021 Jul; 37(7):1233-1248. PubMed ID: 33651656
[TBL] [Abstract][Full Text] [Related]
74. Second-generation antipsychotics and seizures - a systematic review and meta-analysis of serious adverse events in randomized controlled trials.
Reichelt L; Efthimiou O; Leucht S; Schneider-Thoma J
Eur Neuropsychopharmacol; 2023 Mar; 68():33-46. PubMed ID: 36640732
[TBL] [Abstract][Full Text] [Related]
75. The efficacy and heterogeneity of antipsychotic response in schizophrenia: A meta-analysis.
McCutcheon RA; Pillinger T; Mizuno Y; Montgomery A; Pandian H; Vano L; Marques TR; Howes OD
Mol Psychiatry; 2021 Apr; 26(4):1310-1320. PubMed ID: 31471576
[TBL] [Abstract][Full Text] [Related]
76. Long-term metabolic and cardiovascular effects of antipsychotic drugs. A meta-analysis of randomized controlled trials.
Rotella F; Cassioli E; Calderani E; Lazzeretti L; Ragghianti B; Ricca V; Mannucci E
Eur Neuropsychopharmacol; 2020 Mar; 32():56-65. PubMed ID: 31917068
[TBL] [Abstract][Full Text] [Related]
77. Run-in periods and clinical outcomes of antipsychotics in dementia: A meta-epidemiological study of placebo-controlled trials.
Hulshof TA; Zuidema SU; Gispen-de Wied CC; Luijendijk HJ
Pharmacoepidemiol Drug Saf; 2020 Feb; 29(2):125-133. PubMed ID: 31730266
[TBL] [Abstract][Full Text] [Related]
78. Evaluation of Differences in Individual Treatment Response in Schizophrenia Spectrum Disorders: A Meta-analysis.
Winkelbeiner S; Leucht S; Kane JM; Homan P
JAMA Psychiatry; 2019 Oct; 76(10):1063-1073. PubMed ID: 31158853
[TBL] [Abstract][Full Text] [Related]
79. The risk of elevated prolactin levels in pediatric patients exposed to antipsychotics for the treatment of schizophrenia and schizophrenia spectrum disorders: protocol for a systematic review and meta-analysis.
Druyts E; Eapen S; Wu P; Thorlund K
Syst Rev; 2014 Oct; 3():116. PubMed ID: 25312992
[TBL] [Abstract][Full Text] [Related]
80. Are Randomized Controlled Trials on Pharmacotherapy and Psychotherapy for Positive Symptoms of Schizophrenia Comparable? A Systematic Review of Patient and Study Characteristics.
Bighelli I; Leucht C; Huhn M; Reitmeir C; Schwermann F; Wallis S; Davis JM; Leucht S
Schizophr Bull; 2020 Apr; 46(3):496-504. PubMed ID: 32275756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
